Please assess the completion status of the following clinical trial:

Trial Title: The HAM Infliximab Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are able to give informed consent~* Are 16 years or older~* Have 'definite' HAM/TSP according to the criteria of Definite HAM/TSP agreed in Belem 200361~* Have early or progressing disease as defined here:~  * Early HAM/TSP: Patients must have motor disability (minimum of stiffness or weakness) for less than 2 years. (Bladder symptoms if the original and only presenting symptoms as assessed by history are not included)~* Progressing HAM/TSP~* New or worsening motor symptoms in a patient with definite HAM of \> 2 years duration within the last 3 months~Exclusion Criteria:~* Hepatitis B or hepatitis C infection~* HIV infection~* Overt sepsis, abscesses or opportunistic infections~* Active TB (untreated or on treatment)~* Strongyloides stercoralis (untreated)~* Known hypersensitivity to inflixmab, other murine proteins or to any of the excipients~* Malignancy~* Moderate or severe heart failure (NYHA class III/IV)~* Pregnancy or breastfeeding~* Unhealed surgical wounds~* Planned impending surgery - treatment would be withheld for 2-4 weeks prior to major surgery and started/restarted post-operatively if no evidence of infection and wound healing is satisfactory~* Current immunosuppressive or immunomodulatory therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).